絞り込み

16641

広告

Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.

著者 Ageno W , Mantovani LG , Haas S , Kreutz R , Monje D , Schneider J , van Eickels M , Gebel M , Zell E , Turpie AG
Lancet Haematol.2016 Jan ; 3(1):e12-e21.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (259view , 0users)

Full Text Sources

Medical

Miscellaneous

The efficacy and safety of the anticoagulant rivaroxaban for the treatment and secondary prevention of deep-vein thrombosis and pulmonary embolism has been shown in phase 3 trials. However, data about rivaroxaban use in routine clinical practice are needed.
PMID: 26765643 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード